Hiperkalcemia
Rokowania, prognozy i postęp choroby
Rokowanie w hiperkalcemii jest ściśle związane z etiologią, stopniem nasilenia zaburzeń oraz skutecznością terapii. W hiperkalcemii nowotworowej (HCM) rokowanie jest niekorzystne, z medianą przeżycia około 68 dni, a śmiertelność sięga 50% w ciągu 30 dni i 75% w ciągu 3 miesięcy mimo farmakologicznej korekcji stężenia wapnia. Czynniki pogarszające rokowanie to zaawansowane stadium nowotworu (IV), mechanizm zależny od PTHrP (mediana przeżycia 52 dni), niewydolność nerek oraz ciężka hiperkalcemia. W szpiczaku mnogim hiperkalcemia stanowi istotny czynnik prognostyczny, skracając medianę przeżycia do około 40 miesięcy w porównaniu do 57 miesięcy u pacjentów bez hiperkalcemii, co podkreśla jej humoralny mechanizm i rolę uszkodzenia nerek (81,8% przypadków ciężkiej hiperkalcemii).
Leczenie hiperkalcemii nowotworowej, obejmujące bisfosfoniany i terapię przeciwko RANKL, skutecznie normalizuje stężenie wapnia, jednak nie przekłada się to na istotną poprawę długoterminowego rokowania, które pozostaje niekorzystne z powodu zaawansowania choroby podstawowej. Wczesne wykrycie i intensywna terapia hiperkalcemii są kluczowe dla poprawy jakości życia i umożliwienia wcześniejszego wypisu ze szpitala, zwłaszcza w opiece paliatywnej, gdzie istotne jest regularne monitorowanie i kompleksowa kontrola stężenia wapnia. W hiperkalcemii łagodnej, niezwiązanej z nowotworami, rokowanie jest zazwyczaj dobre. Decyzje terapeutyczne powinny uwzględniać cele opieki oraz możliwości dalszych terapii przeciwnowotworowych, podkreślając konieczność wczesnej identyfikacji i adekwatnego leczenia hiperkalcemii jako powikłania zaawansowanej choroby nowotworowej.
Hiperkalcemia – Rokowanie (przewidywanie wyniku leczenia)
Rokowanie w hiperkalcemii zależy od przyczyny wywołującej ten stan, nasilenia zaburzeń oraz skuteczności zastosowanego leczenia. Podstawowym czynnikiem determinującym rokowanie jest chorobą podstawowa, która doprowadziła do hiperkalcemii, a także ciężkość wzrostu stężenia wapnia w surowicy.1
Hiperkalcemia w chorobach nowotworowych
Hiperkalcemia towarzysząca nowotworom złośliwym (HCM – Hypercalcemia of Malignancy) jest uznawana za metaboliczną sytuację nagłą w onkologii i wymaga pilnego, intensywnego leczenia. Pomimo dostępnych metod terapeutycznych, rokowanie w tych przypadkach pozostaje niekorzystne.2 Badania wskazują, że około 50% pacjentów z hiperkalcemią w przebiegu choroby nowotworowej umiera w ciągu 30 dni od rozpoznania, a nawet do 75% pacjentów umiera w ciągu trzech miesięcy, mimo skutecznego wyrównania stężenia wapnia metodami farmakologicznymi.34
W jednym z badań wykazano, że mediana przeżycia pacjentów z hiperkalcemią w przebiegu nowotworów wynosi około 68 dni, co sugeruje, że hiperkalcemia nowotworowa sama w sobie wskazuje na niekorzystne rokowanie, pomimo skutecznej korekcji stężenia wapnia.5 Hiperkalcemia jest czterokrotnie częstsza w nowotworach w IV stadium zaawansowania i wiąże się z gorszym rokowaniem.6
Czynniki wpływające na rokowanie w hiperkalcemii nowotworowej
Na rokowanie w hiperkalcemii nowotworowej wpływa kilka istotnych czynników:
- Rodzaj nowotworu – pacjenci z nowotworami hematologicznymi mają znacznie lepsze rokowanie z medianą przeżycia wynoszącą około 362 dni, w porównaniu do guzów litych7
- Mechanizm hiperkalcemii – hiperkalcemia zależna od PTHrP (parathyroid hormone-related protein) wiąże się z gorszym rokowaniem i medianą przeżycia wynoszącą tylko 52 dni8
- Funkcja nerek – zaburzenia czynności nerek komplikują przebieg hiperkalcemii i pogarszają rokowanie9
- Nasilenie hiperkalcemii – ciężka hiperkalcemia wiąże się z gorszym rokowaniem10
Hiperkalcemia w szpiczaku mnogim
W przypadku nowo zdiagnozowanego szpiczaka mnogiego (NDMM), hiperkalcemia jest szczególnie niekorzystnym czynnikiem prognostycznym. Pacjenci z hiperkalcemią w przebiegu szpiczaka mnogiego mają znacząco gorsze wskaźniki przeżycia – mediana przeżycia wynosi około 40 miesięcy w porównaniu do 57 miesięcy u pacjentów bez tego powikłania.11 Negatywny wpływ prognostyczny hiperkalcemii utrzymuje się zarówno w analizie jednoczynnikowej, jak i w modelu wieloczynnikowym uwzględniającym wiek i stadium R-ISS.12
Co ważne, badania wykazują, że miejscowe zmiany kostne nie są najważniejszym czynnikiem powodującym hiperkalcemię w szpiczaku mnogim. Autorzy przypuszczają, że główną przyczyną jest hiperkalcemia humoralna. Wysoki odsetek uszkodzenia nerek (81,8%) wśród pacjentów z ciężką hiperkalcemią sugeruje istotną rolę nerek w patogenezie hiperkalcemii w szpiczaku.13
Efektywność leczenia a rokowanie
Wyniki leczenia hiperkalcemii nowotworowej są zróżnicowane. W jednym z badań zaobserwowano poprawę u 64,5% pacjentów z hiperkalcemią, podczas gdy u 16,1% stan pozostał stabilny, a 19,4% zmarło w trakcie trwania badania.14 Autorzy podkreślają korzyści płynące z leczenia hiperkalcemii nowotworowej, mimo że ogólne rokowanie pozostaje niekorzystne.15
Jakkolwiek bisfosfoniany i terapia skierowana przeciwko ligandowi receptora aktywatora czynnika jądrowego kappa B (RANKL) są skuteczne w uzyskaniu normalizacji stężenia wapnia, to ogólne rokowanie pozostaje niepomyślne.16 Ponieważ hiperkalcemia jest często oznaką zaawansowanego hormonalnie nowotworu, normalizacja stężenia wapnia może nie poprawiać znacząco długoterminowego rokowania.17
Znaczenie wczesnego wykrywania i leczenia
Wczesne wykrywanie i leczenie hiperkalcemii jest kluczowe dla poprawy wyników leczenia pacjentów i umożliwienia wcześniejszego wypisu ze szpitala.18 Chociaż leczenie ciężkiej hiperkalcemii we wczesnych stadiach może złagodzić objawy, ma ono ograniczony wpływ na oczekiwaną długość życia.19
Dla specjalistów medycyny paliatywnej istotne jest wczesne rozpoznanie hiperkalcemii i opracowanie kompleksowego planu opieki obejmującego regularne monitorowanie i kontrolę stężenia wapnia. Takie podejście optymalizuje wyniki leczenia, łagodzi cierpienie i poprawia jakość życia, zapewniając pacjentom najbardziej skuteczną i spersonalizowaną opiekę.20
Rokowanie w hiperkalcemii łagodnej
W przypadku łagodnej hiperkalcemii spowodowanej chorobami nienowotworowymi lub przejściowymi zaburzeniami, rokowanie jest zazwyczaj dobre.21 Pacjenci z hiperkalcemią wywołaną przez nowotwory często doświadczają objawów i wymagają częstych hospitalizacji, co wiąże się z gorszym rokowaniem.22
Decyzje terapeutyczne a rokowanie
Hiperkalcemia jest częstym powikłaniem onkologicznym, które często wskazuje na krótkie rokowanie. Decyzja o podjęciu leczenia powinna być podejmowana po wcześniejszym określeniu celów opieki i ocenie możliwości zastosowania przyszłych systemowych terapii przeciwnowotworowych.23 Hiperkalcemia nowotworowa jest potencjalnie śmiertelnym, nierozpoznanym i niedostatecznie leczonym powikłaniem zaawansowanej choroby nowotworowej, dlatego kluczowe znaczenie ma jej wczesna identyfikacja i wdrożenie odpowiedniego leczenia.24
Przypadek opisany w literaturze podkreśla znaczenie wnikliwej analizy wszystkich szczegółów związanych z chorobą pacjenta, co może wpłynąć na precyzyjniejsze rokowanie i dobór optymalnego leczenia.25
Kolejne rozdziały
Zapraszamy do dalszego czytania naszego leksykonu.
Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.
Materiały źródłowe
- #1 Hypercalcemia: What It Is, Causes, Symptoms & Treatmenthttps://my.clevelandclinic.org/health/diseases/14597-hypercalcemia
Prognosis, like treatment, depends on the cause and severity of hypercalcemia. When hypercalcemia happens due to a benign condition or temporary situation, it generally has a good prognosis. […] People who have hypercalcemia due to cancer often experience symptoms and require frequent hospitalizations.
- #2 Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergencyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10072174/
Background: Management of hypercalcemia is based on the manifestation of symptoms and serum calcium levels. It is considered an oncological emergency; therefore, management has to be done on an urgent basis. […] Conclusion: Hypercalcemia of malignancy is considered a metabolic oncological emergency and requires urgent and aggressive management. It gets complicated by a deranged kidney function test. Despite available treatment, it portends an abysmal prognosis. […] Although bisphosphonates and receptor activators for nuclear factor kappa B ligand (RANKL) therapy are adequate to attain normocalcemia, the overall prognosis remains grave. Around 50% of patients die within 30 days, and up to 75% die within three months of diagnosis. […] In the present study, median survival was 68 days, comparable to previous studies. This suggests HOM itself portends a dismal prognosis despite hypercalcemia being corrected with medical measures. […] Even if serum calcium is normalized, the prognosis remains poor and patients are candidates for the best supportive care.
- #3 Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergencyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10072174/
Background: Management of hypercalcemia is based on the manifestation of symptoms and serum calcium levels. It is considered an oncological emergency; therefore, management has to be done on an urgent basis. […] Conclusion: Hypercalcemia of malignancy is considered a metabolic oncological emergency and requires urgent and aggressive management. It gets complicated by a deranged kidney function test. Despite available treatment, it portends an abysmal prognosis. […] Although bisphosphonates and receptor activators for nuclear factor kappa B ligand (RANKL) therapy are adequate to attain normocalcemia, the overall prognosis remains grave. Around 50% of patients die within 30 days, and up to 75% die within three months of diagnosis. […] In the present study, median survival was 68 days, comparable to previous studies. This suggests HOM itself portends a dismal prognosis despite hypercalcemia being corrected with medical measures. […] Even if serum calcium is normalized, the prognosis remains poor and patients are candidates for the best supportive care.
- #4 FF #151 Hypercalcemia of Malignancy | Palliative Care Network of Wisconsinhttps://www.mypcnow.org/fast-fact/hypercalcemia-of-malignancy/
Up to 30 percent of patients with cancer develop hypercalcemia. Approximately 50% of these patients will die within 30 days of a hypercalcemia diagnosis, even if the hypercalcemia is corrected, which suggests that hypercalcemia is a sign of a hormonally advanced cancer. […] Hypercalcemia is a common oncologic complication that often portends a short prognosis. The decision to attempt reversal should be made after first exploring the goals of care and assessing the feasibility of future systemic anti-cancer treatments.
- #5 Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergencyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10072174/
Background: Management of hypercalcemia is based on the manifestation of symptoms and serum calcium levels. It is considered an oncological emergency; therefore, management has to be done on an urgent basis. […] Conclusion: Hypercalcemia of malignancy is considered a metabolic oncological emergency and requires urgent and aggressive management. It gets complicated by a deranged kidney function test. Despite available treatment, it portends an abysmal prognosis. […] Although bisphosphonates and receptor activators for nuclear factor kappa B ligand (RANKL) therapy are adequate to attain normocalcemia, the overall prognosis remains grave. Around 50% of patients die within 30 days, and up to 75% die within three months of diagnosis. […] In the present study, median survival was 68 days, comparable to previous studies. This suggests HOM itself portends a dismal prognosis despite hypercalcemia being corrected with medical measures. […] Even if serum calcium is normalized, the prognosis remains poor and patients are candidates for the best supportive care.
- #6https://journals.lww.com/md-journal/fulltext/2021/04090/severe_hypercalcemia_in_a_patient_with_chronic.16.aspx
Hypercalcemia is a common finding in patients with advanced-stage cancers. Paraneoplastic hypercalcemia is commonly associated with dismal prognoses, with survival rates of about 3 months. […] It is 4 times more common in stage IV cancers and is associated with a poor prognosis. […] As a rule, PTHrP- mediated hypercalcemia is associated with a poor prognosis and a median survival of only 52 days. […] Nevertheless, patients with hematologic malignancies had substantially better outcomes with a median survival of 362 days. […] The patient under discussions was known to have a high risk CLL and exhibited a HCM diagnosed on the basis of a low level of PTH, a low normal level of 25 (OH) vitamin D and 1.25 (OH) vitamin D. […] This case highlights the importance of close attendance to all details related to a patient’s presenting illness.
- #7https://journals.lww.com/md-journal/fulltext/2021/04090/severe_hypercalcemia_in_a_patient_with_chronic.16.aspx
Hypercalcemia is a common finding in patients with advanced-stage cancers. Paraneoplastic hypercalcemia is commonly associated with dismal prognoses, with survival rates of about 3 months. […] It is 4 times more common in stage IV cancers and is associated with a poor prognosis. […] As a rule, PTHrP- mediated hypercalcemia is associated with a poor prognosis and a median survival of only 52 days. […] Nevertheless, patients with hematologic malignancies had substantially better outcomes with a median survival of 362 days. […] The patient under discussions was known to have a high risk CLL and exhibited a HCM diagnosed on the basis of a low level of PTH, a low normal level of 25 (OH) vitamin D and 1.25 (OH) vitamin D. […] This case highlights the importance of close attendance to all details related to a patient’s presenting illness.
- #8https://journals.lww.com/md-journal/fulltext/2021/04090/severe_hypercalcemia_in_a_patient_with_chronic.16.aspx
Hypercalcemia is a common finding in patients with advanced-stage cancers. Paraneoplastic hypercalcemia is commonly associated with dismal prognoses, with survival rates of about 3 months. […] It is 4 times more common in stage IV cancers and is associated with a poor prognosis. […] As a rule, PTHrP- mediated hypercalcemia is associated with a poor prognosis and a median survival of only 52 days. […] Nevertheless, patients with hematologic malignancies had substantially better outcomes with a median survival of 362 days. […] The patient under discussions was known to have a high risk CLL and exhibited a HCM diagnosed on the basis of a low level of PTH, a low normal level of 25 (OH) vitamin D and 1.25 (OH) vitamin D. […] This case highlights the importance of close attendance to all details related to a patient’s presenting illness.
- #9 Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergencyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10072174/
Background: Management of hypercalcemia is based on the manifestation of symptoms and serum calcium levels. It is considered an oncological emergency; therefore, management has to be done on an urgent basis. […] Conclusion: Hypercalcemia of malignancy is considered a metabolic oncological emergency and requires urgent and aggressive management. It gets complicated by a deranged kidney function test. Despite available treatment, it portends an abysmal prognosis. […] Although bisphosphonates and receptor activators for nuclear factor kappa B ligand (RANKL) therapy are adequate to attain normocalcemia, the overall prognosis remains grave. Around 50% of patients die within 30 days, and up to 75% die within three months of diagnosis. […] In the present study, median survival was 68 days, comparable to previous studies. This suggests HOM itself portends a dismal prognosis despite hypercalcemia being corrected with medical measures. […] Even if serum calcium is normalized, the prognosis remains poor and patients are candidates for the best supportive care.
- #10 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Hypercalcemia is one of the most common complications of advanced malignancy. […] This study aims to explore treatment outcomes of hypercalcemia among advanced cancer patients so that palliative care physicians can design costeffective and efficient approaches to diagnosis and treatment for these patients. […] The management of HCM depends on the severity of the calcium increase and the specific symptoms present. Patients suffering from HCM usually need prompt management because if left untreated, the prognosis could be fatal. […] Although treatment of severe HCM in its early stages can improve symptoms, it has a limited impact on life expectancy. […] Malignant hypercalcemia is a potentially fatal, undiagnosed, and undertreated complication of advanced malignancy. It is essential for palliative care physicians to identify hypercalcemia and develop comprehensive care plan to optimize the treatment outcomes.
- #11 Hypercalcemia in Multiple Myeloma Leads to Poor Prognosishttps://www.ajmc.com/view/hypercalcemia-in-multiple-myeloma-leads-to-poor-prognosis
Hypercalcemia is caused by many factors in patients with newly diagnosed multiple myeloma (NDMM) and is associated with poor rates of survival, according to a new study. […] Patients who had hypercalcemia faced significantly worse survival rates, with a median of 40 months compared to 57 months in patients without the complication. The negative prognostic effect held up both in a univariate analysis and in a multivariate model that included adjustments for age and R-ISS stage. […] Thus, hypercalcemia mainly caused by localized bone disease could not well explain our clinical insights, the investigators said. While local bone lesions seem to be related to hypercalcemia, they said, such lesions are not the most important factor. […] Instead, the authors suspect that humoral hypercalcemia is the main cause of hypercalcemia in MM. They said the high rate of kidney impairment (81.8%) among patients with severe hypercalcemia suggests the kidneys have an important role in hypercalcemia.
- #12 Hypercalcemia in Multiple Myeloma Leads to Poor Prognosishttps://www.ajmc.com/view/hypercalcemia-in-multiple-myeloma-leads-to-poor-prognosis
Hypercalcemia is caused by many factors in patients with newly diagnosed multiple myeloma (NDMM) and is associated with poor rates of survival, according to a new study. […] Patients who had hypercalcemia faced significantly worse survival rates, with a median of 40 months compared to 57 months in patients without the complication. The negative prognostic effect held up both in a univariate analysis and in a multivariate model that included adjustments for age and R-ISS stage. […] Thus, hypercalcemia mainly caused by localized bone disease could not well explain our clinical insights, the investigators said. While local bone lesions seem to be related to hypercalcemia, they said, such lesions are not the most important factor. […] Instead, the authors suspect that humoral hypercalcemia is the main cause of hypercalcemia in MM. They said the high rate of kidney impairment (81.8%) among patients with severe hypercalcemia suggests the kidneys have an important role in hypercalcemia.
- #13 Hypercalcemia in Multiple Myeloma Leads to Poor Prognosishttps://www.ajmc.com/view/hypercalcemia-in-multiple-myeloma-leads-to-poor-prognosis
Hypercalcemia is caused by many factors in patients with newly diagnosed multiple myeloma (NDMM) and is associated with poor rates of survival, according to a new study. […] Patients who had hypercalcemia faced significantly worse survival rates, with a median of 40 months compared to 57 months in patients without the complication. The negative prognostic effect held up both in a univariate analysis and in a multivariate model that included adjustments for age and R-ISS stage. […] Thus, hypercalcemia mainly caused by localized bone disease could not well explain our clinical insights, the investigators said. While local bone lesions seem to be related to hypercalcemia, they said, such lesions are not the most important factor. […] Instead, the authors suspect that humoral hypercalcemia is the main cause of hypercalcemia in MM. They said the high rate of kidney impairment (81.8%) among patients with severe hypercalcemia suggests the kidneys have an important role in hypercalcemia.
- #14 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Overall improvement was observed in 64.5% of hypercalcemic patients, while 16.1% remained stable, and 19.4% died during the period of our study, reflecting the effectiveness of the provided medical interventions. […] Based on our findings, we support the benefits of treating hypercalcemia of malignancy. […] Early detection and treatment are crucial for improving patient outcomes and facilitating earlier discharge from the hospital. […] It is essential for palliative care providers to identify HCM and develop a comprehensive care plan that includes regular monitoring and management of calcium levels. This approach optimizes treatment outcomes, alleviates suffering, and enhances quality of life, ensuring patients receive the most effective and personalized care possible.
- #15 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Overall improvement was observed in 64.5% of hypercalcemic patients, while 16.1% remained stable, and 19.4% died during the period of our study, reflecting the effectiveness of the provided medical interventions. […] Based on our findings, we support the benefits of treating hypercalcemia of malignancy. […] Early detection and treatment are crucial for improving patient outcomes and facilitating earlier discharge from the hospital. […] It is essential for palliative care providers to identify HCM and develop a comprehensive care plan that includes regular monitoring and management of calcium levels. This approach optimizes treatment outcomes, alleviates suffering, and enhances quality of life, ensuring patients receive the most effective and personalized care possible.
- #16 Treatment Outcomes and Survival in Hypercalcemia of Malignancy: A Grave Metabolic Emergencyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10072174/
Background: Management of hypercalcemia is based on the manifestation of symptoms and serum calcium levels. It is considered an oncological emergency; therefore, management has to be done on an urgent basis. […] Conclusion: Hypercalcemia of malignancy is considered a metabolic oncological emergency and requires urgent and aggressive management. It gets complicated by a deranged kidney function test. Despite available treatment, it portends an abysmal prognosis. […] Although bisphosphonates and receptor activators for nuclear factor kappa B ligand (RANKL) therapy are adequate to attain normocalcemia, the overall prognosis remains grave. Around 50% of patients die within 30 days, and up to 75% die within three months of diagnosis. […] In the present study, median survival was 68 days, comparable to previous studies. This suggests HOM itself portends a dismal prognosis despite hypercalcemia being corrected with medical measures. […] Even if serum calcium is normalized, the prognosis remains poor and patients are candidates for the best supportive care.
- #17 FF #151 Hypercalcemia of Malignancy | Palliative Care Network of Wisconsinhttps://www.mypcnow.org/fast-fact/hypercalcemia-of-malignancy/
Up to 30 percent of patients with cancer develop hypercalcemia. Approximately 50% of these patients will die within 30 days of a hypercalcemia diagnosis, even if the hypercalcemia is corrected, which suggests that hypercalcemia is a sign of a hormonally advanced cancer. […] Hypercalcemia is a common oncologic complication that often portends a short prognosis. The decision to attempt reversal should be made after first exploring the goals of care and assessing the feasibility of future systemic anti-cancer treatments.
- #18 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Overall improvement was observed in 64.5% of hypercalcemic patients, while 16.1% remained stable, and 19.4% died during the period of our study, reflecting the effectiveness of the provided medical interventions. […] Based on our findings, we support the benefits of treating hypercalcemia of malignancy. […] Early detection and treatment are crucial for improving patient outcomes and facilitating earlier discharge from the hospital. […] It is essential for palliative care providers to identify HCM and develop a comprehensive care plan that includes regular monitoring and management of calcium levels. This approach optimizes treatment outcomes, alleviates suffering, and enhances quality of life, ensuring patients receive the most effective and personalized care possible.
- #19 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Hypercalcemia is one of the most common complications of advanced malignancy. […] This study aims to explore treatment outcomes of hypercalcemia among advanced cancer patients so that palliative care physicians can design costeffective and efficient approaches to diagnosis and treatment for these patients. […] The management of HCM depends on the severity of the calcium increase and the specific symptoms present. Patients suffering from HCM usually need prompt management because if left untreated, the prognosis could be fatal. […] Although treatment of severe HCM in its early stages can improve symptoms, it has a limited impact on life expectancy. […] Malignant hypercalcemia is a potentially fatal, undiagnosed, and undertreated complication of advanced malignancy. It is essential for palliative care physicians to identify hypercalcemia and develop comprehensive care plan to optimize the treatment outcomes.
- #20 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Overall improvement was observed in 64.5% of hypercalcemic patients, while 16.1% remained stable, and 19.4% died during the period of our study, reflecting the effectiveness of the provided medical interventions. […] Based on our findings, we support the benefits of treating hypercalcemia of malignancy. […] Early detection and treatment are crucial for improving patient outcomes and facilitating earlier discharge from the hospital. […] It is essential for palliative care providers to identify HCM and develop a comprehensive care plan that includes regular monitoring and management of calcium levels. This approach optimizes treatment outcomes, alleviates suffering, and enhances quality of life, ensuring patients receive the most effective and personalized care possible.
- #21 Hypercalcemia: What It Is, Causes, Symptoms & Treatmenthttps://my.clevelandclinic.org/health/diseases/14597-hypercalcemia
Prognosis, like treatment, depends on the cause and severity of hypercalcemia. When hypercalcemia happens due to a benign condition or temporary situation, it generally has a good prognosis. […] People who have hypercalcemia due to cancer often experience symptoms and require frequent hospitalizations.
- #22 Hypercalcemia: What It Is, Causes, Symptoms & Treatmenthttps://my.clevelandclinic.org/health/diseases/14597-hypercalcemia
Prognosis, like treatment, depends on the cause and severity of hypercalcemia. When hypercalcemia happens due to a benign condition or temporary situation, it generally has a good prognosis. […] People who have hypercalcemia due to cancer often experience symptoms and require frequent hospitalizations.
- #23 FF #151 Hypercalcemia of Malignancy | Palliative Care Network of Wisconsinhttps://www.mypcnow.org/fast-fact/hypercalcemia-of-malignancy/
Up to 30 percent of patients with cancer develop hypercalcemia. Approximately 50% of these patients will die within 30 days of a hypercalcemia diagnosis, even if the hypercalcemia is corrected, which suggests that hypercalcemia is a sign of a hormonally advanced cancer. […] Hypercalcemia is a common oncologic complication that often portends a short prognosis. The decision to attempt reversal should be made after first exploring the goals of care and assessing the feasibility of future systemic anti-cancer treatments.
- #24 Treatment Outcomes of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh: An Observational Studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11635692/
Hypercalcemia is one of the most common complications of advanced malignancy. […] This study aims to explore treatment outcomes of hypercalcemia among advanced cancer patients so that palliative care physicians can design costeffective and efficient approaches to diagnosis and treatment for these patients. […] The management of HCM depends on the severity of the calcium increase and the specific symptoms present. Patients suffering from HCM usually need prompt management because if left untreated, the prognosis could be fatal. […] Although treatment of severe HCM in its early stages can improve symptoms, it has a limited impact on life expectancy. […] Malignant hypercalcemia is a potentially fatal, undiagnosed, and undertreated complication of advanced malignancy. It is essential for palliative care physicians to identify hypercalcemia and develop comprehensive care plan to optimize the treatment outcomes.
- #25https://journals.lww.com/md-journal/fulltext/2021/04090/severe_hypercalcemia_in_a_patient_with_chronic.16.aspx
Hypercalcemia is a common finding in patients with advanced-stage cancers. Paraneoplastic hypercalcemia is commonly associated with dismal prognoses, with survival rates of about 3 months. […] It is 4 times more common in stage IV cancers and is associated with a poor prognosis. […] As a rule, PTHrP- mediated hypercalcemia is associated with a poor prognosis and a median survival of only 52 days. […] Nevertheless, patients with hematologic malignancies had substantially better outcomes with a median survival of 362 days. […] The patient under discussions was known to have a high risk CLL and exhibited a HCM diagnosed on the basis of a low level of PTH, a low normal level of 25 (OH) vitamin D and 1.25 (OH) vitamin D. […] This case highlights the importance of close attendance to all details related to a patient’s presenting illness.